Jonathan Yen-Wen Yu Sells 300 Shares of Disc Medicine (NASDAQ:IRON) Stock

Posted by George Bondi on Jul 2nd, 2026

Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) COO Jonathan Yen-Wen Yu sold 300 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $72.50, for a total value of $21,750.00. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $3,938,490. This represents a 0.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00.
On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Price Performance

Shares of Disc Medicine stock opened at $74.95 on Thursday. Disc Medicine, Inc. has a 52-week low of $40.00 and a 52-week high of $99.50. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -11.32 and a beta of 0.97. The company has a fifty day moving average of $69.08 and a 200-day moving average of $70.50. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00.

Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). Equities research analysts expect that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on IRON. Wedbush reiterated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Morgan Stanley boosted their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.80.

Get Our Latest Report on IRON

Institutional Investors Weigh In On Disc Medicine

Several hedge funds have recently made changes to their positions in IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Disc Medicine by 22.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock worth $756,000 after purchasing an additional 2,807 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Disc Medicine by 1,277.1% during the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after buying an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Disc Medicine by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after buying an additional 3,454 shares in the last quarter. Legal & General Group Plc grew its position in shares of Disc Medicine by 18.0% in the 2nd quarter. Legal & General Group Plc now owns 24,097 shares of the company’s stock worth $1,276,000 after buying an additional 3,682 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Disc Medicine by 21.6% in the 2nd quarter. Invesco Ltd. now owns 16,817 shares of the company’s stock worth $891,000 after acquiring an additional 2,983 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

Disc Medicine Company Profile

(Get Free Report)

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.